David Barton talks to ecancer at EAPM 2017 in Belfast.

He discusses the need for better quality in genetic testing of tumour and patient genotyping.

He explains how by running assessments of the quality of this genotyping, he sees a worrying number of incorrect results, particularly with the adoption of new technologies.

These are mainly due to simple human errors.

свернуть